LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it ...
LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT®, its ...
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of ...
LAGUNA HILLS, Calif., Nov. 30, 2017 /PRNewswire/ -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today that ...
LAGUNA HILLS, Calif., March 28, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the ...
Prelude Corp. (dba Preludedx) reported positive results from the SweDCIS randomized trial showing its DCISionrt test predicts radiation benefit for lowering 10-year local invasive breast cancer risk.
LAGUNA HILLS, Calif. , Dec. 8, 2020 /PRNewswire/ -- Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, will present clinical ...
Prelude Corp. (dba Preludedx) reported positive results from the SweDCIS randomized trial showing its DCISionrt test predicts radiation benefit for lowering 10-year local invasive breast cancer risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results